Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study.
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
/ administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Body Mass Index
Chemotherapy, Adjuvant
Disease Progression
Female
Humans
Male
Middle Aged
Prognosis
Retrospective Studies
Stomach Neoplasms
/ diagnosis
Survival Analysis
Treatment Outcome
Weight Loss
/ drug effects
Ramucirumab
Advanced gastric cancer
Body mass index
Body weight loss
Prognostic factors
Ramucirumab
Second-line chemotherapy
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
28
04
2019
accepted:
02
07
2019
pubmed:
8
7
2019
medline:
29
8
2019
entrez:
8
7
2019
Statut:
ppublish
Résumé
This multicenter retrospective study aims to evaluate the correlations between Body Weight Loss (BWL), Body Mass Index (BMI) and clinical outcomes (ORR, PFS, and OS) of advanced gastric cancer (aGC) patients treated with second-line ramucirumab-based therapy in a "real-life" setting. From December 2014 to October 2018, 101 consecutive aGC patients progressed to a first-line chemotherapy were treated with ramucirumab alone (10.9%) or in combination with paclitaxel (89.1%). Median BMI was 21.2 kg/m Efficacy of ramucirumab is confirmed in this "real-life" analysis. BWL seems not to have correlations with clinical outcomes in these patients, while BMI and ECOG-PS remain major prognostic factors. A possible explanation for the lack of prognostic effect of BWL might be the proportion of patients subjected to PTR in this series (52.5%).
Identifiants
pubmed: 31280347
doi: 10.1007/s00432-019-02971-7
pii: 10.1007/s00432-019-02971-7
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2365-2373Références
Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB et al (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 17(12):1697–1708
doi: 10.1016/S1470-2045(16)30531-9
pubmed: 27776843
Aoyama T, Sato T, Maezawa Y, Kano K, Hayashi T, Yamada T et al (2017) Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer. Int J Clin Oncol. 22(3):476–483. https://doi.org/10.1007/s10147-017-1089-y (Epub 2017 Feb 7)
doi: 10.1007/s10147-017-1089-y
pubmed: 28176023
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemoterapy versus chemoterapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open label, randomised controlled trial. Lancet 376(9742):687–697
doi: 10.1016/S0140-6736(10)61121-X
pubmed: 20728210
Chen S, Nie RC, OuYang LY, Li YF, Xiang J, Zhou ZW et al (2017) Body mass index (BMI) may be a prognostic factor for gastric cancer with peritoneal dissemination. World J Surg Oncol. 15(1):52. https://doi.org/10.1186/s12957-016-1076-1
doi: 10.1186/s12957-016-1076-1
pmcid: 5322670
pubmed: 28228146
Cortellini A, Cannita K, Parisi A, Venditti O, Lanfiuti Baldi P, De Berardis B et al (2018) Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: a single institution experience with the FD/FOx regimen. Oncol Rep 40(2):803–812. https://doi.org/10.3892/or.2018.6475 (Epub 2018 Jun 6)
doi: 10.3892/or.2018.6475
pubmed: 29901103
Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc (Series B) 74:187–200
Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36–46. https://doi.org/10.1056/NEJMoa073149
doi: 10.1056/NEJMoa073149
pubmed: 18172173
Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM et al (2018) Ramucirumab as second-line therapy in metastatic gastric cancer: real-world data from the RAMoss study. Target Oncol. 13(2):227–234. https://doi.org/10.1007/s11523-018-0562-5
doi: 10.1007/s11523-018-0562-5
pubmed: 29582224
Ebinger SM, Warschkow R, Tarantino I, Schmied BM, Güller U, Schiesser M (2016) Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis. Gastric Cancer 19(3):723–734. https://doi.org/10.1007/s10120-015-0541-9 (Epub 2015 Sep 21)
doi: 10.1007/s10120-015-0541-9
pubmed: 26391158
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
doi: 10.1016/j.ejca.2008.10.026
Ejaz A, Spolverato G, Kim Y, Poultsides GA, Fields RC, Bloomston M et al (2015) Impact of body mass index on perioperative outcomes and survival after resection for gastric cancer. J Surg Res 195(1):74–82. https://doi.org/10.1016/j.jss.2014.12.048 (Epub 2014 Dec 31)
doi: 10.1016/j.jss.2014.12.048
pubmed: 25619462
Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F et al (2014) Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer 50(7):1330–1344. https://doi.org/10.1016/j.ejca.2014.01.029 (Epub 2014 Mar 17)
doi: 10.1016/j.ejca.2014.01.029
pubmed: 24650579
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–39
doi: 10.1016/S0140-6736(13)61719-5
pubmed: 24094768
Fuchs CS, Muro K, Tomasek J, Van Cutsem E, Cho JY, Oh SC et al (2017) Prognostic factor analysis of overall survival in gastric cancer from two phase III studies of second-line ramucirumab (REGARD and RAINBOW) using pooled patient data. J Gastric Cancer. 17(2):132–144
doi: 10.5230/jgc.2017.17.e16
pmcid: 5489542
pubmed: 28680718
Hartgrink HH, Putter H, Klein Kranenbarg E, Bonenkamp JJ, van de Velde CJ, Dutch Gastric Cancer Group (2002) Value of palliative resection in gastric cancer. Br J Surg. 89(11):1438–1443
doi: 10.1046/j.1365-2168.2002.02220.x
pubmed: 12390389
Izuishi K, Mori H (2016) Recent strategies for treating stage IV gastric cancer: roles of palliative gastrectomy, chemotherapy, and radiotherapy. J Gastrointestin Liver Dis. 25(1):87–94. https://doi.org/10.15403/jgld.2014.1121.251.rv2
doi: 10.15403/jgld.2014.1121.251.rv2
pubmed: 27014758
Janmaat VT, Steyerberg EW, Van Der Gaast A, Mathijssen RH, Bruno MJ, Peppelenbosch MP et al (2017) Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev. 11:CD004063. https://doi.org/10.1002/14651858.cd004063.pub4
doi: 10.1002/14651858.cd004063.pub4
pubmed: 29182797
Jun DH, Kim BJ, Park JH, Kim JG, Chi KC, Park JM et al (2016) Preoperative body mass index may determine the prognosis of advanced gastric cancer. Nutr Cancer. 68(8):1295–1300 (Epub 2016 Oct 7)
doi: 10.1080/01635581.2016.1224363
pubmed: 27715329
Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG et al (2018) Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer 21(5):819–830. https://doi.org/10.1007/s10120-018-0806-1 (Epub 2018 Feb 9)
doi: 10.1007/s10120-018-0806-1
pubmed: 29427038
Kaplan EL, Meier P (1958) Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457–481
doi: 10.1080/01621459.1958.10501452
Kim KH, Park DJ, Park YS, Ahn SH, Park DJ, Kim HH (2017) Actual 5-year nutritional outcomes of patients with gastric cancer. J Gastric Cancer. 17(2):99–109. https://doi.org/10.5230/jgc.2017.17.e12 (Epub 2017 May 23)
doi: 10.5230/jgc.2017.17.e12
pmcid: 5489549
pubmed: 28680715
Komatsu S, Kosuga T, Kubota T, Okamoto K, Konishi H, Shiozaki A et al (2018) Preoperative low weight affects long-term outcomes following curative gastrectomy for gastric cancer. Anticancer Res 38(9):5331–5337. https://doi.org/10.21873/anticanres.12860
doi: 10.21873/anticanres.12860
pubmed: 30194185
Kubo H, Komatsu S, Ichikawa D, Kawaguchi T, Kosuga T, Okamoto K et al (2016) Impact of body weight loss on recurrence after curative gastrectomy for gastric cancer. Anticancer Res 36(2):807–813
pubmed: 26851044
Kulig J, Sierzega M, Kolodziejczyk P, Dadan J, Drews M, Fraczek M (2010) Implications of overweight in gastric cancer: a multicenter study in a Western patient population. Eur J Surg Oncol 36(10):969–976. https://doi.org/10.1016/j.ejso.2010.07.007 (Epub 2010 Aug 21)
doi: 10.1016/j.ejso.2010.07.007
pubmed: 20727706
Lee SE, Lee JH, Ryu KW, Nam B, Kim CG, Park SR et al (2012) Changing pattern of postoperative body weight and its association with recurrence and survival after curative resection for gastric cancer. Hepatogastroenterology. 59(114):430–435. https://doi.org/10.5754/hge09218
doi: 10.5754/hge11415
pubmed: 22353511
Lee HH, Park JM, Song KY, Choi MG, Park CH (2016) Survival impact of postoperative body mass index in gastric cancer patients undergoing gastrectomy. Eur J Cancer 52:129–137. https://doi.org/10.1016/j.ejca.2015.10.061 (Epub 2015 Dec 10)
doi: 10.1016/j.ejca.2015.10.061
pubmed: 26686912
Lin YS, Huang KH, Lan YT, Fang WL, Chen JH, Lo SS et al (2013) Impact of body mass index on postoperative outcome of advanced gastric cancer after curative surgery. J Gastrointest Surg. 17(8):1382–1391. https://doi.org/10.1007/s11605-013-2238-x (Epub 2013 May 29)
doi: 10.1007/s11605-013-2238-x
pubmed: 23715652
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725–730
doi: 10.1056/NEJMoa010187
pubmed: 11547741
Matsumoto H, Kawazoe A, Shimada K, Fukuoka S, Kuboki Y, Bando H et al (2018) A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites. BMC Cancer. 18(1):120. https://doi.org/10.1186/s12885-018-4057-7
doi: 10.1186/s12885-018-4057-7
pmcid: 5793350
pubmed: 29385993
Moriwaki Y, Kunisaki C, Kobayashi S, Harada H, Imai S, Kasaoka C (2003) Does body mass index (BMI) influence morbidity and long-term survival in gastric cancer patients after gastrectomy? Hepatogastroenterology. 50(49):284–288
pubmed: 12630042
Murahashi S, Takahari D, Wakatsuki T, Fukuda N, Ichimura T, Ogura M et al (2018) A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma. Int J Clin Oncol. 23(1):92–97. https://doi.org/10.1007/s10147-017-1192-0 (Epub 2017 Sep 14)
doi: 10.1007/s10147-017-1192-0
pubmed: 28913565
Ock CY, Oh DY, Lee J, Kim TY, Lee KH, Han SW et al (2016) Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. Gastric Cancer 19(2):597–606. https://doi.org/10.1007/s10120-015-0481-4 (Epub 2015 Mar 8)
doi: 10.1007/s10120-015-0481-4
pubmed: 25749718
Park YS, Park DJ, Lee Y, Park KB, Min SH, Ahn SH et al (2018) Prognostic roles of perioperative body mass index and weight loss in the long-term survival of gastric cancer patients. Cancer Epidemiol Biomark Prev 27(8):955–962. https://doi.org/10.1158/1055-9965.EPI-18-0122 (Epub 2018 May 21)
doi: 10.1158/1055-9965.EPI-18-0122
Paulson AS, Hess LM, Liepa AM, Cui ZL, Aguilar KM, Clark J et al (2018) Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices. Gastric Cancer 21(5):831–844. https://doi.org/10.1007/s10120-018-0796-z (Epub 2018 Feb 3)
doi: 10.1007/s10120-018-0796-z
pubmed: 29397460
Schemper M, Smith TL (1997) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343–346
doi: 10.1016/0197-2456(96)00075-X
Shah MA, Janjigian YY, Stoller R, Shibata S, Kemeny M, Krishnamurthi S et al (2015) Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US gastric cancer consortium. J Clin Oncol 33(33):3874–3879
doi: 10.1200/JCO.2015.60.7465
pubmed: 26438119
Takayoshi K, Uchino K, Nakano M, Ikejiri K, Baba E (2017) Weight loss during initial chemotherapy predicts survival in patients with advanced gastric cancer. Nutr Cancer 69(3):408–415. https://doi.org/10.1080/01635581.2017.1267774 (Epub 2017 Jan 19)
doi: 10.1080/01635581.2017.1267774
pubmed: 28102709
Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H (2016) Gastric cancer. Lancet 388(10060):2654–2664. https://doi.org/10.1016/S0140-6736(16)30354-3 (Epub 2016 May 5)
doi: 10.1016/S0140-6736(16)30354-3
pubmed: 27156933
Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235
doi: 10.1016/S1470-2045(14)70420-6
pubmed: 25240821
Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29(13):1715–1721. https://doi.org/10.1200/JCO.2010.33.0597 (Epub 2011 Mar 28)
doi: 10.1200/JCO.2010.33.0597
pubmed: 21444866